A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies

Trial Profile

A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary)
  • Indications B cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms PILOT
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 20 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 14 May 2018 Planned End Date changed from 15 Jun 2022 to 2 Aug 2022.
    • 14 May 2018 Planned primary completion date changed from 15 Jun 2022 to 2 Aug 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top